Elisa Greggio

LRRK2 regulates synaptic function through modulation of actin cytoskeletal dynamics

This study shows that LRRK2 regulates synaptic function by modulating actin cytoskeletal dynamics through BDNF signaling in neurons.

Leucine-rich repeat kinase 2 impairs the release sites of Parkinson's disease vulnerable dopamine axons

This study identifies LRRK2's role in impairing dopamine axon release sites in Parkinson's disease, leading to reduced dopamine release and synaptic dysfunction.

Evolutionary divergence of LRRK2 interaction domains contributes to human- and mouse-specific protein interaction networks

This study shows that evolutionary divergence in LRRK2 interaction domains leads to species-specific protein interaction networks in humans and mice.

Loss of catalytic activity and impaired proteostasis in guanosine nucleotide-depleted LRRK2

This study investigates the functional consequences of catalytic activity loss in LRRK2, showing impaired proteostasis and altered interactome in guanosine nucleotide-depleted Lrrk2.

Regulation between LRRK2 and PP2A signaling in cellular models of Parkinsons disease

This study identifies a regulatory feedback loop between LRRK2 and PP2A phosphatases in Parkinson's disease, showing that LRRK2 phosphorylates PP2A to disrupt its function and contribute to neuronal death.

Parkinson disease-associated protein DJ-1 regulates the autophagic-lysosomal pathway through ROS-dependent modulation of the AMPK/mTORC1 axis.

This study shows that DJ-1 deficiency impairs autophagosome-lysosome fusion and lysosomal degradation, leading to autophagic substrate accumulation through ROS-dependent modulation of the AMPK/mTORC1 axis in Parkinson's disease.

Nuclear ASC speck formation in microglia is associated with inflammasome priming and is exacerbated in LRRK2-G2019S Parkinson disease

This study shows that LRRK2-G2019S mutation in microglia increases nuclear ASC speck formation, indicating a primed inflammasome state linked to chronic neuroinflammation in Parkinson's disease.

Identification and characterization of nanobodies acting as molecular chaperones for glucocerebrosidase through a novel allosteric mechanism

This study identifies nanobodies that act as molecular chaperones for glucocerebrosidase, improving its activity and stability, with potential therapeutic applications for Gaucher and Parkinson's diseases.

LRRK2 mediates haloperidol-induced changes in indirect pathway striatal projection neurons

This study shows that LRRK2 kinase mediates haloperidol-induced motor side effects in striatal neurons, suggesting LRRK2 as a target to reduce antipsychotic side effects.

PAK6 rescues pathogenic LRRK2-mediated ciliogenesis and centrosomal cohesion defects in a mutation-specific manner

This study identifies PAK6 as a modifier of LRRK2 mutations, showing it rescues ciliogenesis defects in G2019S but not R1441C mutations.

PAK6 promotes neuronal autophagy by regulating TFEB nuclear translocation.

This study identifies PAK6 as a positive regulator of neuronal autophagy through TFEB nuclear translocation, with implications for neurodegenerative disease treatment.

Prospective role of PAK6 and 14-3-3 gamma as biomarkers for Parkinson's disease

This study quantifies PAK6 and 14-3-3 gamma in plasma to assess their potential as biomarkers for diagnosing sporadic and LRRK2-linked Parkinson's disease.

Investigation of microglial diversity in a mouse model of Parkinson's disease pathology

This study investigates the role of CLEC7A-positive microglia and dark microglia in a mouse model of Parkinson's disease with the LRRK2 G2019S mutation, revealing their association with cellular stress and pathology.

The activities of LRRK2 and GCase are positively correlated in clinical biospecimens and experimental models of Parkinson's disease

The paper investigates the relationship between LRRK2 and GCase activities in Parkinson's disease models and biospecimens, finding a positive correlation.

Trafficking of the glutamate transporter is impaired in LRRK2-related Parkinson's disease

This study shows that the LRRK2 G2019S mutation impairs EAAT2 trafficking, leading to reduced glutamate clearance and potential neurodegeneration in Parkinson's disease.

DOPAL initiates αSynuclein-mediated impaired proteostasis in neuronal projections leading to enhanced vulnerability in Parkinson's disease.

This study shows DOPAL promotes αSynuclein accumulation and impairs proteostasis in neuronal projections, contributing to Parkinson's disease progression.

LRRK2 G2019S kinase activity triggers neurotoxic NSF aggregation

This study shows that LRRK2 G2019S kinase activity promotes NSF aggregation, which is toxic to neurons, and that autophagy can clear these aggregates and improve motor and cognitive function in a mouse model.